Overall , intervention groups obtained higher 25(OH)D concentration than controls and there was obvious dose – response effect between intake dose and 25(OH)D concentration .
Baseline 25(OH)D concentration and age were significant indicators for 25(OH)D concentration .
Conclusions Regional- and age-specific recommended dosages of VitD supplements for population to achieve optimal 25(OH)D concentrations have been suggested
Background / Objectives Optimal doses of vitamin D ( VitD ) supplement in different population s are unclear .
We aim to evaluate the relationship between VitD supplementation and post-intervention serum 25-hydroxyvitamin D [ 25(OH)D ] concentration , to provide a recommended dosage of VitD for achieving an optimal 25(OH)D concentration for different population s .
The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial.
OBJECTIVE Epidemiological data suggest low serum 25-hydroxyvitamin D3 ( 25-OH-D3 ) levels are associated with radiological progression of knee osteoarthritis ( OA ) . This study aim ed to assess whether vitamin D supplementation can slow the rate of progression . METHOD A 3-year , double-blind , r and omised , placebo-controlled trial of 474 patients aged over 50 with radiographically evident knee OA comparing  800 IU cholecalciferol daily with placebo . Primary outcome was difference in rate of medial joint space narrowing ( JSN ) . Secondary outcomes included lateral JSN , Kellgren & Lawrence grade , Western Ontario and McMaster Universities Osteoarthritis Index ( WOMAC ) pain , function , stiffness and the Get up and Go test . RESULTS Vitamin D supplementation  increased 25-OH-D3 from an average of 20.7 ( st and ard deviation ( SD ) 8.9 ) μg/L to 30.4 ( SD 7.7 ) μg/L , compared to 20.7 ( SD 8.1 ) μg/L and 20.3 ( SD 8.1 ) μg/L in the placebo group . There was no significant difference in the rate of JSN over 3 years in the medial compartment of the index knee between the treatment group ( average -0.01 mm/year ) and placebo group ( -0.08 mm/year ) , average difference 0.08 mm/year ( 95 % confidence interval ( CI ) [ -0.14 - 0.29 ] , P = 0.49 ) . No significant interaction was found between baseline vitamin D levels and treatment effect . There were no significant differences for any of the secondary outcome measures . CONCLUSION Vitamin D supplementation did not slow the rate of JSN or lead to reduced pain , stiffness or functional loss over a 3-year period . On the basis of these findings we consider that vitamin D supplementation has no role in the management of knee OA
Overall , intervention groups obtained higher 25(OH)D concentration than controls and there was obvious dose – response effect between intake dose and 25(OH)D concentration .
Baseline 25(OH)D concentration and age were significant indicators for 25(OH)D concentration .
Conclusions Regional- and age-specific recommended dosages of VitD supplements for population to achieve optimal 25(OH)D concentrations have been suggested
Background / Objectives Optimal doses of vitamin D ( VitD ) supplement in different population s are unclear .
We aim to evaluate the relationship between VitD supplementation and post-intervention serum 25-hydroxyvitamin D [ 25(OH)D ] concentration , to provide a recommended dosage of VitD for achieving an optimal 25(OH)D concentration for different population s .